Matarin Capital Management LLC Decreased Its Stake in Enanta Pharmaceuticals INC (ENTA) by $2.53 Billion

Big Money Sentiment decreased to 1.5 in 2018 Q2. It has change of 0.16, from 2018Q1’s 1.66. The ratio dived due to ENTA positioning: 16 sold and 46 reduced. 34 funds acquired positions and 59 increased positions. Investors holded 14.18 million in 2018Q1 but now own 14.64 million shares or 3.25% more. State Of Wisconsin Inv Board invested 0.01% of its capital in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Morgan Stanley stated it has 51,767 shs. Baldwin Brothers Ma holds 1,000 shs or 0.02% of its capital. Metropolitan Life Insur Co reported 5,474 shs stake. American Century accumulated 32,428 shs or 0% of the stock. California State Teachers Retirement stated it has 25,638 shs or 0.01% of all its holdings. Swiss Commercial Bank owns 0% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 25,000 shs. Caxton Associate Lp reported 3,311 shs or 0.02% of all its holdings. Zeke Capital Advsrs Ltd Liability Corp has invested 0.02% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Goldman Sachs Grp Inc Inc holds 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) or 120,695 shs. Guggenheim Capital Ltd Com stated it has 11,123 shs or 0.01% of all its holdings. Blackrock Inc owns 2.43 million shs. 519,035 were reported by Krensavage Asset Ltd Liability. Jacobs Levy Equity Mgmt Inc reported 12,677 shs stake. Prudential Financial holds 0.05% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) or 302,587 shs.

ENTA registered $6.27 million net activity with 0 insider buys and 5 insider sales since June 11, 2018. 4,155 shs were sold by Adda Nathalie, worth $383,596. 35,000 shs were sold by Luly Jay R., worth $4.38 million on Thursday, July 5.

Matarin Capital Management Llc decreased its stake by 9.76% in Enanta Pharmaceuticals Inc. (ENTA), according to 2018Q2 Securities and Exchange filling. The company’s stock sank 21.40% while Matarin Capital Management Llc sold 21,804 shares. The institutional investor is holding 201,703 shares, compared to the 223,507 from the previous quarter. And the announced value of the health care company is $23.38B for the 2018Q2. $1.42 billion is the market cap of Enanta Pharmaceuticals Inc.. ENTA hit $73.03 during the last trading session after $1.42 change.Enanta Pharmaceuticals, Inc. is uptrending after having risen 110.33% since December 8, 2017. ENTA has 351,022 volume or 27.78% up from normal. ENTA outperformed the S&P 500 by 94.71%.

Matarin Capital Management Llc operates about $198.00 million and $1382.93B US Long portfolio. It rose its stake in Urban Outfitters Inc. (NASDAQ:URBN) by 6,681 shares to 21,473 shares, valued at $956.62 million in 2018Q2, according to the filing. Matarin Capital Management Llc has risen its stake in Mcgrath Rentcorp (NASDAQ:MGRC) and also increased its holding in Science Applications International Corp. (NYSE:SAIC) by 3,285 shares in the quarter, for a total of 139,521 shares.

On February, 6 is expected Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)’s earnings report, as reported by Faxor. Analysts forecast $1.64 earnings per share. That’s $0.86 up or 110.26 % from 2017’s earnings of $0.78. If ENTA’s EPS is $1.64 the profit will be $31.87M for 11.13 P/E. After $1.30 EPS report previous quarter, Wall Street now predicts 26.15 % EPS growth of Enanta Pharmaceuticals, Inc..

For more Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) news posted recently go to:,,, or The titles are as follows: “Earnings Scheduled For November 26, 2018 – Benzinga” posted on November 26, 2018, “This Small Biotech Is Building on a Surprising Success – The Motley Fool” on April 24, 2018, “Trade of the Day: Celgene Is Coiling Up for a Rally – Yahoo Finance” with a publish date: August 29, 2018, “Why Enanta Pharmaceuticals (ENTA) Could Shock the Market Soon – Nasdaq” and the last “Oversold Conditions For Enanta Pharmaceuticals (ENTA) – Nasdaq” with publication date: August 08, 2018.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.